In This Section

Cardiovascular Consequences of Metabolic Targeting in Obesity

Wednesday April 25, 2018

8:30 am - 11:00 am Eastern Time (ET)

Room 16B


Chair :

Amy Arnold
Penn State College of Medicine

Debra Diz
Wake Forest School of Medicine

Obesity is increasing at an alarming rate worldwide. The majority of obese patients have hypertension, which increases risk for cardiovascular disease. While there is a well-established clinical association, there is an unmet need to better understand integrative molecular and hormonal mechanisms underlying cardiovascular and metabolic derangements in obesity. A failure to consider overlap in the pathways regulating these functions has led to adverse cardiovascular effects of several anti-obesity drugs. This symposium will highlight the need to study integrative cardiometabolic mechanisms in obesity, and will describe potential pharmacologic targets with evidence for positive metabolic and cardiovascular effects in this disease.


Philipp Scherer - The University of Texas Southwestern Medical Center

Adiponectin: An Emerging Adipokine Mediator of Cardiovascular and Metabolic Health

Amy Arnold - Penn State College of Medicine

Angiotensin-(1-7): A Positive Force for Cardiometabolic Function

Dongsheng Cai - Albert Einstein College of Medicine

Hypothalamic Inflammation: A Novel Target Linking Energy Imbalance and Hypertension in Obesity

Debra Diz - Wake Forest School of Medicine

The Endocannabinoid System and Cardiometabolic Risk Factors

Korin Leffler - East Carolina University, Brody School of Medicine

Disrupted Adiponectin-Connexin43 Signaling Underlies the Exacerbated Myocardial Dysfunction in Diabetic Female Rats

Rebecca Fleeman - University of Florida

Angiotensin-(1-7)-Mediated Increases in Energy Expenditure Appear Independent of the Hypothalamic Melanocortin System

Amanda Soler - New York Medical College

Intra-Abdominal Lipectomy Reduces Large Arterial Stiffness and Blood Pressure in Metabolic Syndrome